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Summary: Katacalcin is a recently discovered peptide, contained within the calcitonin precursor. For the
highly sensitive readioimmunological measurement of katacalcin and calcitonin we used extraction on C-18,
thereby lowering the detection limits in seram to 0.8 pmol/1 (katacalcin) and 0.7 pmol/1 (calcitonin), and
simultaneously improving the specificities of both assays for the monomeric forms of the peptides. Extraction
recoveries were > 96% and > 95% for pure monoiodinated [125I]Tyr(0)-katäcalcin and [125I]calcitonin,
respectively; and 95—98% and 91 —97% respectively for the corresponding unlabelled peptides. This method
is süfficiently sensitive and specific for studies on the physiology of both peptides. Gel filtration of serum
from a patient with mediillary carcinoma of the thyroid showed that the majority of high molecular weight
forms of katacalcin and calcitonin did not bind to C-18, and that the eluted material consisted to more than
90% of monomeric katacalcin and calcitonin. Basal levels (mean ± SEM) of katacalcin were higher in men
(3.0 ± 0.6 pmol/1, age < 40 years, and 1.8 ± 0.4 pmol/1, age > 40 years) and younger women (2.1 ± 0.4
pmol/1) than in older women (1.3 ± 0.6 pmol/1; p< 0.02). The respective values for calcitonin were 5.1 ± 0.9
and 4.0 ± 0.6 pmöl/1 for young and older men, and 2.3 ± 0.4 und 2.8 ± 0.8 pmol/1 for young and older
women, with a significant sex-related difference in both age groups. Basal serum levels of katacalcin and
calcitonin were highly correlated (katacalcin = 0.66 calcitonin —0.12 pmol/1; p < 0.001). Calcium infusions
(2 mg/kg body weight) in 30 normal subjects showed a significantly lower secretory capacity for katacalcin
and calcitonin in older women, but no correlation between basal level and peak levels after five minutes.
The peptides were undetectable in 5 (katacalcin) and 4 (calcitonin) out of 11 athyroid patients, and they
were higher in patients on haemodialysis.
Bestimmung von zirkulierendem monomeren Katakalcin und Calcitonin
Zusammenfassung: Katakalcin ist ein kürzlich entdecktes Peptid, das Teil der Calcitonin-Vorstufe ist. Wir
haben eine C-18 Extraktionsmethöde entwickelt, mit der Katakalcin und Calcitonin aus biologischen Proben
angereichert und danach mit hoher Spezifität und Sensitivität (0,8 pmol/1 für Katakalcin und 0,7 pmol/1 für
Calcitonin) radioimmunologisch bestimmt werden können. Die Wiederfindungsraten von reinem monoiodier-
') Supported by the Lorenz Böhler Stiftung.
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tem [125I]Tyr(0)-Katakalcin und [125I]Calcitonin waren > 96% und > 95%, bzw. 95-98% und 91-97% für
die unmarkierten Peptide. Diese Methodik erwies sich als ausreichend empfindlich und spezifisch für Studien
zur Physiologie der beiden Peptide. Gelfiltration von Serum eines Patienten mit medullärem Schilddrüsenkar-
zinom zeigte, daß der Großteil der Katakalcin- und Calcitonin-Fraktionen mit hohem Molekulargewicht
nicht an C-18 bindet und daß das eluierte Material zu mehr als 90% aus monomerem Katakalcin und
Calcitonin besteht. Basale Konzentrationen (Mittel ± SEM) von Männern (3,0 ± 0,tf pmol/1, Alter < 40
Jahre, und 1,8 ± 0,4 pmol/1, Alter > 40 Jahre) und jungen Frauen (2,1 + 0,4 pmol/1) waren höher als von
älteren Frauen (1,3 ± 0,6 pmol/1; p < 0,02). Die entsprechenden Calcitonin-Werte betrugen für Frauen
2,3 + 0,4 und 2,8 ± 0,8 pmol/1, und für Männer 5,1 ± 0,9 bzw. 4,0 ± 0,6 pmol/1, mit einem geschlechtsabhän-
gigen Unterschied in beiden Altersgruppen. Basale Katakalcin- und Calcitonin-Konzentrationen kontierten
signifikant (Katakalcin = 0,66 Calcitonin -0,12 pmol/1; p < 0,001). Calciuminfusionen (2 mg/kg Körperge-
wicht) in 30 Normalpersonen ergaben eine signifikant niedrigere Sekretionsreserve für Katakalcin und
Calcitonin in älteren Frauen, es bestand aber keine Korrelation zwischen basalen und stimulierten Werten.
Katakalcin und Calcitonin waren in 5 bzw. 4 von 11 athyreoten Patienten nicht nachweisbar und bei
hämodialysierten Patienten erhöht.
Introduction
Calcitonin is a small peptide hormone synthesized
and secreted mainly by the C-cells of the thyroid. As
for many other secretory peptides, the first transla-
tion product is a larger precursor peptide, whose
amino acid sequence was deduced from analysis of
the cDNA of the calcitonin gene (l, 2). Human calci-
tonin resides towards the C-terminal end of this pre-
cursor and is flanked on its C-terminal side by a 21
amino acid peptide named PDN-21 (3) or katacalcin
(4). At present, it is uncertain whether synthetic kata-
calcin has biological activity similar to that of calci-
tonin (5), which is so far the only hormone known
to lower serum calcium concentration. Although
regulated by fluctuations of serum calcium in the
physiological ränge (6), the physiological significance
of calcitonin is still unclear and the influence of
katacalcin has not yet been studied in detail. The
continuing controversies about basal and stimulated
values, sex- and age-dependence and diurnal varia-
tions are complicated by the technical difficulties of
assaying calcitonin in biological fluids. One of the
causes for the discrepant results reported in the literä-
ture (7) seems to be the marked immunoheterogeneity
of glandular (8) and circulating (9, 10) human calci-
tonin. While most antisera were raised against syn-
thetic monomeric calcitonin, they nevertheless cross-
react with other forms of circulating calcitonin. Simi-
lar effects have been described for other peptide hor-
mones, but no data on the heterogeneity of katacalcin
have been reported. Recently, simple extraction
methods were described that allow the detennination
of monomeric calcitonin, the major biologically ac-
tive form of calcitonin (11). A similar approach was
also reported for katacalcin (4). Since few data are
available on normal levels of katacalcin and their
relation to calcitonin, we have developed a procedure
that allows the simultaneous extraction, purification
and concentration of calcitonin and katacalcin from
small biological specimens before radioimmunoassay,
and we have applied this method to physiological
studies of calcitonin and katacalcin.
Materials and Methods
Disposable C-18 SEP-PAK cartridges (Wateis Associates Inc.,
Milford, MA) were wetted with 2ml methanol and washed
with 3ml water/methanol/trifluoroacetic acid (95/5/0.1, by
vol.). Three ml plasma were acidifled with l ml l mol/1 HC1
and fed by gravity slowly through each cartridge, followed by
three washes with l ml water/methanol/trifluoroacetic acid (95/
5/0.1, by vol.) each. Adsorbed katacalcin was quantitatively
eluted with 3 ml water/acetone/trifhioroacetic acid (75/25/0.1,
by vol.) and calcitonin with 3 ml water/acetone/trifluoroacetic
acid (55/45/0.1, by vol.). For routine purposes both peptides
were eluted simultaneously with. 4ml water/acetpne/triflup-
roacetic acid (55/45/0.1, by vol.). The eluates were partially
evaporated at 37 °C under a stream of nitrqgen, frozen and
lyophilized. On the day of the assay, the lyophilised residues
were dissolved in 0.6ml RIA buffer (20 mmol/1 Tris/HCl,
pH 8.5,10 g/l bovine serum albumin, 0.2 g/l NaN3 and 0.3 ml/l
Tween 20). Katacalcin and calcitonin were determined in 24
hour/24 hour non-equilibrium radioimmunoassays in a total
volume of 300 with incubation at 4 °C. Antisera (Cambridge
Research Biochemicals, Harston, UK) were used in half the
recommended quantity. Synthetic peptides (Peninsula Labora^
tories Inc., Belmont, CA) were used äs Standards and äs starting
material for the tracers, which were prepared from Tyr(O)-
katacalcin and calcitonin by the iodogen method and purified
by chromatofocussing (12). Approx. 10 000 counts/min of pure
monoiodinated peptide were added per tube. Separation was
achieved by addition of a preprecipitated second antibody
(Sonn Biomedica, Saluggia, Italy). Standard curves were run
in triplicate, and usually two sample dilutions were assayed to
check for parallelism. Standard curves were evaluated using a
linear least sqüares fit of logit/log transformed data. Sensitivity
of an assay was defined äs B0-3 SD and, disregarding assay
runs with SD > 2.5% was set at B/B0 0.925. Radibactive
recoveries were determined by subtracting from the total activ-
ity the pereentages eluted düring application and washing Steps
and retained on the cartridge after elution. Gel filtration on
Sephadex G-50 superfine was carried out äs previously de-
scribed (8).
Results are expressed äs the mean ± SEM if not stated other-
wise. For comparison of groups, ;tiie non-parametric rank-
correlation coefficient was used.
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Subjects and study protocol
Specimens were obtained from normal volunteers not having
any noticeable disease and not receiving any medication known
to interfere with calcium metabolism. All samples were taken
and all studies performed in the morning after an overnight
fast. Samples for serum were collected in glass tubes and stored
at 4 °C for one to three hours, then centrifuged. In some cases
EDTA- and heparin-plasma were obtained at the same time.
All samples were kept frozen at —20 °C for not longer than 2
months before extraction and assay.
Basal samples were obtained from 11 athyroid patients, 26
patients on haeraodialysis and 90 healthy individuals (47 men
and 43 women). Four groups were compared: 23 young men
(18-39 years), 30 young women (19—39 years), 24 older men
(40-63 years) and 13 older women (40-76 years).
For Chromatographie Separation of immunoreactive peptides,
the serum of a patient with a medullary carcinoma of the
thyroid was used.
For the calcium loading test, Ca-gluconate (8.5% solution) was
infused i. v. for one minute at a dose of 2 mg/kg body weight
and blood was withdrawn at 0, 5 and 10 minutes. Four groups:
9 young men (19—38 years), 8 young women (19—36 years),
6 older men (42—63 years) and 9 older women (40 — 69 years)
underwent this test.
Results
Validation of the analytical method
The recovery of monoiodinated peptides was checked
with several normal sera and plasmas and with sam-
ples from patients on haemodialysis; recovery was
consistently higher than 96% for Tyr(0)-katacalcin
(98 ± 1%, n = 12), and higher than 95% for calci-
tonin (97 ± 2%, n = 11). Recoveries for unlabelled
peptides were similärly high in the case of katacalcin
(median 96%, ränge 95—98%) and only slightly
lower for calcitonin (median 93%, ränge 91—97%).
In view of the consistently high recovery, results are
giveri without correction. There were no differences
between results obtained in serum or plasma samples
(EDTA or heparin) from the same subjects. Storage
at —20 °C for up to two months did not affect the
results of either assay. The sensitivities of the assays
varied less than 30% and were at leäst 0.8 pmol/1
for katacalcin· and 0.7 pmol/1 for calcitonin. The
coefficients of Variation (between assay) in the useful
ränge of the test (B/B0 0.85—0.15) were not greater
than 14%.
The gel filtration profiles of a serum before (katacal-
cin 10.5 nmol/1, calcitonin 17.3 nmol/1) and after C-
18 extraction (katacalcin 1.77 nmol/1, calcitonin 2.12
nmol/1) and of the eluate are shöwn in figure l. Most
of the katacalcin- and calcitonin-immünofeactivity of
large moleculär weight was not adsorbed and was
recovered in the flow-through, whereas monomeric
peptides were retained and could be eluted.
15 20 25 30 35 40
Effluent [mlj
Fig. 1. Gel filtration profiles of immunoreactive calcitonin and
katacalcin before (—·· ) and after ( ) extrac-
tion by a C-18 cartridge and in the eluate ( )
from the cartridge. 0.2 ml of serum from a patient with
a medullary carcinoma of the thyroid, or the equivalent
volumes of acidified flow through from the C-18 car-
tridge, or of lyophilized and reconstituted eluate were
chromatographed. The vertical arrows represent, from
the left to the right, the elution positions of [125I]calci-
tonin and [3H]leucine. The dashed lines indicate the
detection limits of the radioimmunoassays.
Basal levels and effect of calcium infusions
Basal katacalcin and calcitonin serum levels (tab. 1)
were highly correlated: katacalcin = 0.66 calcitonin
-0.12 pmol/1 (r = 0.82; p < 0.001; fig. 2).
The rise in katacalcin and calcitonin levels after infu-
sion of calcium in each of the four groups is shown
in figure 3. Although peak levels for katacalcin and
calcitonin were lower for older subjects, no significant
age-dependence was seen.






















4.0 ± 0.6 (a)
2.3 ± 0.4
2.8 ± 0.8 (c)
Difference between men and women:
a) p < 0.01
b) p < 0.02
c) p < 0.05
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Fig. 2. Serum levels of extractable katacalcin and calcitonin.
The solid line indicates the regression line fitted by the















Fig. 3. Serum levels of extractable katacalcin and calcitonin
before and after Stimulation by calcium infusion in
normal volunteers.
males: o < 40 years
> 40 years
females: < 40 years
O — - — - > 40 years
Differences between men and women (in the respective
age groups):
*) p < 0.02
**) p < 0.05
Pathological levels
Katacalcin was ündetectable (< 0.8 pmol/l) in 5 out
of 11 athyroid patients, the others had levels between
0.8 and 2.9 pmol/l. Calcitonin levels were up to 4.8
pmol/l and ündetectable in 4 subjects (< 0.7 pmol/l).
In 26 patients on chronic intermittent haemodialysis,
levels of katacalcin were elevated compared to an
age- and sex-matched control group (p< 0.01), and
ranged from 4.1 to 30.8 pmol/l. Calcitonin levels were
between 5.1 and 39.7 pmol/l, also significantly higher
than the control collective (p < 0.02).
Discussion
We report here a simple method for the extraction
and simultaneous purification of katacalcin and calci-
tonin from seruxn or plasma samples using C-18 silica
äs adsorbent material, with a reasonable requirement
of sample volume (3 ml). Compared with the extrac-
tion on silica gel äs described for calcitonin (l 1), this
method gives better recoveries and highly reproduc-
ible extraction characteristics, allowing the Separation
of katacalcin and calcitonin. Much broader and
therefore overlapping elution profiles were found
with silica gel (results not shown). With C-18, simi-
larly high extraction yields have been obtained with
other peptide hormones, such äs endorphins (13) or
human atrial natriuretic peptide (14). Although few
data are published, the direct determination of kata-
calcin seems to suffer from the same limitation äs the
determination of calcitonin and other peptides in
biological samples (4), requiring extraction and con-
centration Steps (15). For calcitonin, improvements
of assay performance, most notably the removal of
variations due to nonspecific factors, has resulted in
an established upper normal limit of approximately
30 pmol/l. Extraction procedures have lowered this
limit to 6 pmol/l (11, 7), One publication reported
equimolar concentrations of katacalcin and calci-
tonin in the serum of normals and patients with
medüllary carcinoma of the thyrpid, Although we
found the concentrations of katacalcin and calcitonin
to be highly correlated, calcitonin levels were not
equimolar (7), but about 50% higher than katacalcin
levels, and individual values did deviate noticeably
from the line of correlation. Since the extraction and
the assay procedure appear to be free from interferen-
ces that might explain this deviation, we conclude
that excretion and metabolism of the twq peptides
must be sufficiently variable to account for the ob-
served differences. In contrast, the general tfends
were practically identical, although the sex-related
difference of basal katacalcin values was not statisti-
cally significant in yoünger females. Lower basäl
levels of both katacalcin and calcitonin were seen in
older women. Since the relative deficiency of calci-
tonin may predispose to bone loss and katacalcin
might influence calcium metabolism, it is necessary
to critically examine the relation of monomeric calci-
tonin and katacalcin deficiency to long tenn skeletal
homeostasis. Since monomeric calcitonin is the main
biologically active fraction of immunoreactive calci-
tonin (16), a similar relation might hold true for
katacalcin and thus mäke the measürements of ex-
tracted, pürified katacalcin more reliable clinically.
Changes in calcitonin and katacalcin levels after cal-
cium Stimulation have been shöwn for women before
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and after ovarectomy, using the same assay procedure
(17). Several groups have reported that the increase
of calcitonin secretion after calcium infusion de-
creases with age. Amongst our normal individuals,
only the older females had significantly reduced peak
values of both katacalcin and calcitonin. However, it
is very difficult to compare these results with pub-
lished data, since different protocols have been used
that may influence the results (l 8). In addition, there
seem to be large ethnic differences in the secretory
capacity of katacalcin and calcitonin, which might
explain reported discrepancies (15). The present data
confirm the sex-related difference of calcitonin levels
and extend this observation to katacalcin levels,
measuring the concentrations of only the monomeric
form of this peptide. Techniques similar to ours
should enable physiological studies on age- and sex-
related bone loss.
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